At Alkermes, our goal is to build a biotechnology company focused on bringing innovative medicines to patients, helping them lead better lives.
Our proprietary technologies, combined with our capabilities to develop, manufacture, and commercialize products, make us unique. The science of what we do enables us to develop highly-differentiated products with the potential to overcome common barriers to treatment success.
Our approach leverages scientific expertise and technology platforms to develop new medicines that offer patients far more than enhanced compliance or convenience. We are committed to developing medications designed to improve clinical outcomes through better efficacy and improved safety.
Our pipeline is also unique. We have partnered with some of the world's best pharmaceutical and biotechnology companies to develop breakthrough products in major diseases such as schizophrenia and diabetes. We are also developing our own products and continue to invest in our proprietary portfolio in therapeutic areas as diverse as addiction and respiratory disease.
We are passionate about our goal and highly optimistic about the future. With two commercial products, an exciting late-stage pipeline, and more than 600 talented, enthusiastic employees, we strive to make a difference for patients every day. We welcome your interest.
Sincerely,
David A. Broecker, President and Chief Executive Officer